首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Design,synthesis and molecular modeling studies on novel moxifloxacin derivatives as potential antibacterial and antituberculosis agents
Institution:1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Haydarpa?a 34668, ?stanbul, Turkey;2. Department of Biology, Recep Tayyip Erdo?an University, 53100 Rize, Turkey;3. Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, 333031 Pilani, India;1. Department of Chemistry and Virginia Tech Center for Drug Discovery, M/C 0212, Virginia Tech, Blacksburg, VA 24061, United States;2. Department of Biochemistry and Virginia Tech Center for Drug Discovery, M/C 0308, Virginia Tech, Blacksburg, VA 24061, United States;3. Department of Biochemistry and Molecular Biology, and Center for Tropical and Emerging Global Diseases (CTEGD), University of Georgia, Athens, GA 30602, United States;4. Centre National d’Application des Recherches Pharmaceutiques, B.P 702, Antananarivo 101, Madagascar;1. College of Pharmacy, Harbin University of Commerce, Harbin, Heilongjiang Province 150076, PR China;2. Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, Wuhan University of Science and Technology, Hubei, PR China;3. DXC PharmaTech (Hubei) Co. Ltd., Hubei, PR China;1. College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China;2. Zhejiang Casnovo Materials Co., Ltd., Zhoushan 316022, China;3. Zhejiang Provincial Engineering Technology Research Center of Marine Biomedical Products, School of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China;1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China;2. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China;3. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, United States;1. Marmara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Haydarpa?a, 34668 ?stanbul, Turkey;2. Marmara University, Faculty of Pharmacy, Department of Biochemistry, Haydarpa?a, 34668 ?stanbul, Turkey;3. KU Leuven, Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, B-3000 Leuven, Belgium;1. SynBioC Research Group, Department of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium;2. Centre for Industrial Biotechnology and Biocatalysis, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium;3. Division of Pharmacology, Department of Medicine, University of Cape Town, K45, OMB Groote Schuur Hospital, Observatory 7925, South Africa;4. Department of Chemistry and Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa
Abstract:Twenty-one novel alkyl/acyl/sulfonyl substituted fluoroquinolone derivatives were designed, synthesized and evaluated for their anti-tuberculosis and antibacterial activity. The targeted compounds were synthesized by the introduction of alkyl, acyl or sulfonyl moieties to the basic secondary amine moiety of moxifloxacin. Structures of the compounds were enlightened by FT-IR, 1H NMR, 13C NMR and HRMS data besides elemental analysis. Compounds were initially tested in vitro for their anti-mycobacterial activity against Mycobacterium tuberculosis H37Rv using microplate alamar blue assay. Minimal inhibitory concentration (MIC) values of all compounds were found between > 25.00–0.39 µg/mL while compounds 1, 2 and 13 revealed an outstanding activity against M. tuberculosis H37Rv with MIC values of 0.39 µg/mL. Activities of compounds 121 against to a number of Gram-positive and Gram-negative bacteria and fast growing mycobacterium strain were also investigated by agar well diffusion and microdilution methods. According to antimicrobial activity results, compound 13 was found the most potent derivative with a IC50 value of <1.23 μg/mL against Staphylococcus aureus and clinical strain of methicillin-resistant clinical strain of S. aureus.
Keywords:Fluoroquinolones  Moxifloxacin  Antibacterial activity  Anti-tuberculosis activity  DNA supercoiling assay  Molecular docking  Resistant strains  FQ"}  {"#name":"keyword"  "$":{"id":"k0045"}  "$$":[{"#name":"text"  "_":"fluoroquinolone  TB"}  {"#name":"keyword"  "$":{"id":"k0055"}  "$$":[{"#name":"text"  "_":"tuberculosis  WHO"}  {"#name":"keyword"  "$":{"id":"k0065"}  "$$":[{"#name":"text"  "_":"World Health Organization  MDR/RR TB"}  {"#name":"keyword"  "$":{"id":"k0075"}  "$$":[{"#name":"text"  "_":"multi-drug resistant/rifampicin resistant tuberculosis  MABA"}  {"#name":"keyword"  "$":{"id":"k0085"}  "$$":[{"#name":"text"  "_":"microplate alamar blue assay
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号